Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Still Confident Of Future Prospects Post-Xarelto

Executive Summary

The German group has been talking up its pharmaceuticals division but analysts are not convinced it has addressed the elephant in the room that is the loss of patent protection for its blockbuster anticoagulant Xarelto in 2024.

Advertisement

Related Content

Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut
FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer
Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion
Keeping Track: Xarelto Earns CV Risk Reduction Claim In Quiet Week; Spotlight On Formal Dispute Resolution
Executive All-Change: Bayer's Weinand To Join Sanofi, While Sanofi's Oelrich To Take His Place At Bayer
COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications
Bayer And Morphosys Brush Off ADC Mesothelioma Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel